Log in

NASDAQ:BIIBBiogen Stock Price, Forecast & News

$306.72
+7.07 (+2.36 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$298.12
Now: $306.72
$308.27
50-Day Range
$292.25
MA: $310.11
$342.55
52-Week Range
$215.77
Now: $306.72
$374.99
Volume1.29 million shs
Average Volume1.15 million shs
Market Capitalization$50.05 billion
P/E Ratio9.47
Dividend YieldN/A
Beta0.54
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More
Biogen logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.72 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.38 billion
Cash Flow$39.53 per share
Book Value$73.93 per share

Profitability

Net Income$5.89 billion

Miscellaneous

Employees7,400
Market Cap$50.05 billion
Next Earnings Date7/28/2020 (Estimated)
OptionableOptionable

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Biogen (NASDAQ:BIIB) Frequently Asked Questions

How has Biogen's stock been impacted by COVID-19 (Coronavirus)?

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BIIB stock has increased by 4.2% and is now trading at $306.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Biogen?

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 sell ratings, 14 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biogen.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Biogen.

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) released its quarterly earnings data on Wednesday, April, 22nd. The biotechnology company reported $9.14 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $7.73 by $1.41. The biotechnology company had revenue of $3.53 billion for the quarter, compared to the consensus estimate of $3.41 billion. Biogen had a net margin of 40.76% and a return on equity of 49.22%. The business's revenue was up 1.3% on a year-over-year basis. During the same quarter last year, the firm earned $6.98 EPS. View Biogen's earnings history.

How will Biogen's stock buyback program work?

Biogen declared that its Board of Directors has initiated a share repurchase plan on Monday, December 23rd 2019, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company's management believes its shares are undervalued.

What price target have analysts set for BIIB?

30 Wall Street analysts have issued 12 month target prices for Biogen's shares. Their forecasts range from $235.00 to $410.00. On average, they anticipate Biogen's stock price to reach $317.46 in the next year. This suggests a possible upside of 3.5% from the stock's current price. View analysts' price targets for Biogen.

Has Biogen been receiving favorable news coverage?

Headlines about BIIB stock have trended somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biogen earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutBiogen.

Are investors shorting Biogen?

Biogen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,170,000 shares, an increase of 9.4% from the April 30th total of 3,810,000 shares. Based on an average daily trading volume, of 2,080,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 2.6% of the company's shares are short sold. View Biogen's Current Options Chain.

Who are some of Biogen's key competitors?

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Walt Disney (DIS), Celgene (CELG), Micron Technology (MU) and Intel (INTC).

Who are Biogen's key executives?

Biogen's management team includes the following people:
  • Mr. Michel Vounatsos, CEO & Director (Age 57)
  • Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 54)
  • Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 62)
  • Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 50)
  • Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 53)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.83%), Primecap Management Co. CA (9.78%), State Street Corp (5.06%), Clearbridge Investments LLC (2.70%), Wellington Management Group LLP (2.51%) and Geode Capital Management LLC (2.07%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin. View institutional ownership trends for Biogen.

Which major investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Clearbridge Investments LLC, Wellington Management Group LLP, AQR Capital Management LLC, Assenagon Asset Management S.A., Fort Washington Investment Advisors Inc. OH, Nuveen Asset Management LLC, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin. View insider buying and selling activity for Biogen.

Which major investors are buying Biogen stock?

BIIB stock was purchased by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, APG Asset Management N.V., Orbimed Advisors LLC, BlackRock Inc., Bank of New York Mellon Corp, Rock Springs Capital Management LP, Redmile Group LLC, and Ardevora Asset Management LLP. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos. View insider buying and selling activity for Biogen.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $306.72.

How big of a company is Biogen?

Biogen has a market capitalization of $50.05 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.